American Oncology Research and MiBA Form Strategic Alliance to Integrate Real-Time Data Intelligence with Community-Based Clinical Research

Rhea-AI Summary

American Oncology Research (AONC) and Meaningful Insights Biotech Analytics (MiBA) announced a strategic alliance on January 15, 2026 to integrate AI-enhanced real-world data into community-based clinical research.

The partnership embeds MiBA’s near-real-time RWD and AI workflows into the American Oncology Network to improve site feasibility, patient matching, enrollment speed, and trial access at the point of care via EMR-integrated insights. The alliance also targets improved trial equity and DAP-aligned enrollment strategies to reduce protocol amendments and support more representative data.

Market Reality Check

Price: $12.00 Vol: Volume 931 is below the 2...

low vol

$12.00 Last Close

Volume Volume 931 is below the 20-day average of 2,285 (relative volume 0.41x). low

Technical Shares at $11.75 are trading above the 200-day MA of $8.79 and 17.54% below the 52-week high of $14.25.

Peers on Argus

AONC fell 2.08% while peers were mixed: HWAIF down 1.87%, WHTCF and ATIP flat, b...

AONC fell 2.08% while peers were mixed: HWAIF down 1.87%, WHTCF and ATIP flat, but HLYK and NUMIF up 21% and 23.91% respectively, pointing to stock-specific dynamics around this news rather than a uniform sector move.

Historical Context

5 past events · Latest: Oct 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Oct 10	Research abstracts	Positive	-1.5%	Multiple AON research abstracts accepted for ASCO Quality 2025 presentations.
Oct 07	Physician addition	Positive	+0.3%	New board-certified medical oncologist joined partner practice in Maryland.
Sep 02	Physician addition	Positive	+2.8%	New oncologist joined Genesis Cancer and Blood Institute in Arkansas.
Aug 12	Growth update	Positive	+2.0%	Reported >$2B annual revenue, >40% growth, network and therapy expansion.
Jul 24	Quality accreditation	Positive	+15.6%	Central laboratory received reaccreditation from the College of American Pathologists.

Pattern Detected

Positive operational and growth updates have more often coincided with price gains, though there has been at least one notable divergence on favorable research-related news.

Recent Company History

Over the past six months, American Oncology Network reported several growth and quality milestones. On Jul 24, reaccreditation of its Central Lab from CAP coincided with a 15.56% gain. On Aug 12, news of annual revenue exceeding $2 billion with over 40% growth and expanded therapies saw shares up 2%. Physician additions in Arkansas (Sep 2) and Maryland (Oct 7) also aligned with modest gains. However, research abstract presentations at ASCO Quality 2025 on Oct 10 saw a 1.47% decline despite positive academic visibility.

Market Pulse Summary

This announcement details a strategic alliance to embed AI-enhanced, real-time data into community-b...

Analysis

This announcement details a strategic alliance to embed AI-enhanced, real-time data into community-based oncology research, aiming to streamline feasibility, startup and enrollment. Recent history shows American Oncology Network emphasizing growth, quality accreditation and expanded therapies, including revenue above $2 billion with over 40% growth. Investors may watch for concrete metrics such as faster trial activation, higher enrollment rates, and better fulfillment of Diversity Action Plan requirements as indicators of the partnership’s operational impact.

Key Terms

real-world data, rwd, electronic medical record, emr, +3 more

7 terms

real-world data medical

"By leveraging MiBA’s deep Real-World Data (RWD) capabilities, AOR can conduct..."

Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.

rwd medical

"By leveraging MiBA’s deep Real-World Data (RWD) capabilities, AOR can conduct..."

Real-world data (RWD) are health and medical information collected outside controlled clinical trials—such as electronic health records, insurance claims, patient registries, wearable devices, and pharmacy records. For investors, RWD is like seeing how a product performs on city streets versus a test track: it reveals how treatments work in everyday practice, helps predict market uptake, supports regulatory and reimbursement decisions, and can reduce uncertainty about a therapy’s real-world value.

electronic medical record medical

"The platform uses targeted insights within the Electronic Medical Record (EMR)..."

An electronic medical record is a digital version of a patient’s chart that stores clinical notes, test results, prescriptions and treatment history in a secure, searchable system—like a locked, organized digital filing cabinet for a doctor’s office or hospital. Investors care because EMR systems drive recurring software and services revenue, affect healthcare providers’ efficiency and costs, and carry regulatory, cybersecurity and interoperability risks that can influence a company’s profitability and valuation.

emr medical

"The platform uses targeted insights within the Electronic Medical Record (EMR)..."

An electronic medical record (EMR) is a digital version of a patient’s paper chart used by a single clinic or hospital to store medical history, test results, prescriptions and treatment notes. For investors, EMR systems matter because they drive recurring software and service revenue, affect healthcare providers’ costs and efficiency, and carry regulatory, privacy and interoperability risks that can influence adoption, contract value and long‑term market growth.

diversity action plan regulatory

"The partnership also strengthens the industry’s ability to meet Diversity Action Plan (DAP)..."

A diversity action plan is a formal set of steps an organization commits to take to increase representation, fairness and inclusion across its workforce and leadership—like a road map that names goals, timelines and measures of progress. Investors care because clearer plans can reduce reputational and regulatory risk, improve employee retention and innovation, and provide a way to track whether a company is managing talent and social expectations responsibly—similar to checking a maintenance schedule for a long-term investment.

ai-powered intelligence technical

"By embedding AI-powered intelligence into AOR’s clinical workflows, we are not just..."

AI-powered intelligence is automated insight generated by computer systems that analyze large amounts of data to spot patterns, make predictions, or summarize information—like a digital assistant that reads thousands of reports and highlights what matters. For investors it matters because these systems can speed up research, flag risks or opportunities that a person might miss, and help make faster, more informed decisions, though outputs still require human judgment.

clinical trial protocols medical

"the disconnect between static clinical trial protocols and the dynamic reality..."

A clinical trial protocol is the written plan that describes exactly how a medical study will be conducted — who can join, what treatments or tests participants will receive, how results are measured, and the schedule of procedures. For investors, the protocol is like a recipe or blueprint that determines how reliable and timely the study’s results are, shaping the chances of regulatory approval, development costs, and the timeline for potential marketable products.

AI-generated analysis. Not financial advice.

FORT MYERS, Fla., Jan. 15, 2026 (GLOBE NEWSWIRE) -- American Oncology Research, LLC (AOR), and Meaningful Insights Biotech Analytics, LLC (MiBA), today announced a strategic partnership designed to align operational infrastructure with advanced data intelligence in community oncology. By integrating AOR’s site management capabilities with MiBA’s AI-enhanced data ecosystem, the alliance creates a unified framework that closes gaps between study design, site feasibility and patient access.

The collaboration addresses a longstanding challenge in the pharmaceutical industry: the disconnect between static clinical trial protocols and the dynamic reality of patient care. By embedding intelligent data workflows directly into the American Oncology Network (AON), the partnership aims to shift clinical research from a reactive administrative process to a proactive, data-informed discipline.

"To truly advance patient care, we must modernize the infrastructure that supports it," said Katie Goodman, vice president of research at American Oncology Research. "Our partnership with MiBA moves beyond traditional site management by operationalizing real-time data. This allows us to identify friction points before they occur—whether in feasibility, startup or enrollment—ensuring that the speed of research matches the urgency of our patients' needs."

Optimizing the Research Lifecycle 
The alliance focuses on reducing the timeline between site selection and patient enrollment. By leveraging MiBA’s deep Real-World Data (RWD) capabilities, AOR can conduct feasibility analysis and patient matching based on contemporaneous network data. This provides a near-real-time view of eligible patient populations, enabling research teams to validate site viability and mobilize resources with greater precision. 

“Integrating real-time data into community research is essential to closing the gap between trial availability and patient need,” said Ralph V. Boccia, MD, medical director of American Oncology Research. “This partnership strengthens our ability to identify eligible patients sooner, open trials more efficiently and ensure that life-changing therapies are accessible to individuals receiving care close to home.”

"The future of clinical development relies on the seamless convergence of care and research," said Mark Moch, managing partner at MiBA. "We are moving away from fragmented, siloed processes toward an integrated model where insights drive action. By embedding AI-powered intelligence into AOR’s clinical workflows, we are not just identifying patients; we are architecting a system where trials are accessible, efficient and aligned with the provider’s daily workflow."

Enhancing Provider Engagement and Trial Equity
A key component of the strategy is the integration of research opportunities directly into the point of care. The platform uses targeted insights within the Electronic Medical Record (EMR) environment to close the awareness gap for oncologists, ensuring clinical trials are presented as immediate and viable care options rather than retrospective considerations.

The partnership also strengthens the industry’s ability to meet Diversity Action Plan (DAP) requirements. With a holistic, data-driven operational model, AOR can proactively identify demographic barriers and implement inclusive enrollment strategies during study design. This approach reduces the risk of costly protocol amendments and supports more representative, high-quality data generation.

About American Oncology Research (AOR)
American Oncology Research (AOR) helps practices offer cutting-edge clinical trials without added burden. As part of the American Oncology Network (AON), we bring proven expertise, tailored site management services, and advanced tools to local practices—so more patients can access promising treatments right in their own communities.

We partner with research sites to streamline trial operations, from regulatory oversight to patient recruitment, financial tracking, and beyond. Our approach simplifies processes for providers and accelerates access for patients—without compromising quality, compliance, or care.

With AOR, practices can launch or expand trial offerings and deliver innovation locally-shaping the future of cancer care one patient at a time.

About Meaningful Insights Biotech Analytics
Meaningful Insights Biotech Analytics (MiBA) is a healthcare AI technology company on a mission to close the feedback loop between physicians, patients, and industry partners. The technology and data insights that MiBA generates supports pharmaceutical companies, research organizations, payers, biotech, health systems and providers to advance the quality of patient care. Learn more at www.mibaanalytics.com.

About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/769aca83-d193-4ea7-8d2c-0d7daf06ca6a

Contact:
Karen Riley Sawyer-
American Oncology Network
Karen.Sawyer@AONcology.com

FAQ

What did AONC announce on January 15, 2026 with MiBA?

AONC announced a strategic alliance with MiBA to embed AI-powered real-world data into community clinical research to improve feasibility, patient matching, and enrollment.

How will the AONC–MiBA partnership affect patient enrollment for AONC trials?

The partnership aims to provide near-real-time patient matching and feasibility data so sites can validate viability and mobilize resources faster to shorten enrollment timelines.

What is the role of EMR integration in the AONC and MiBA collaboration?

EMR integration delivers targeted trial insights to oncologists at the point of care, increasing awareness and making trials immediate care options rather than retrospective considerations.

Will the AONC–MiBA alliance impact trial diversity for AONC studies (AONC)?

Yes; the alliance includes data-driven operational tools to identify demographic barriers and implement inclusive enrollment strategies aligned with Diversity Action Plan requirements.

Does the partnership between AONC and MiBA change study design or site selection processes?

The collaboration embeds real-time feasibility and site data into workflows to inform study design and improve site selection decisions based on current network populations.

Is the AONC–MiBA integration expected to reduce protocol amendments for AONC studies?

The companies say the data-driven approach aims to reduce costly protocol amendments by identifying potential barriers during study design and enrollment planning.